JAAD ranked most impactful dermatology journal in the world

bruce_thiers_NEW.JPGBy Bruce H. Thiers, MD
Editor, JAAD

The Academy has received some very exciting news about the Journal of the American Academy of Dermatology. For the first time ever, JAAD has been ranked the most impactful dermatology journal in the world.

  jaad-impact-factor-graph.jpg
JAAD's Impact Factor has soared in recent years, making it the most cited dermatology journal in the world.

Toward the end of each academic year, Thomson Reuters releases its report on the impact of scholarly journals published in both clinical and nonclinical fields of study. This is designated the journal’s Impact Factor, which measures the frequency with which the average article in a journal has been cited in a particular year. Stated differently, the Impact Factor is basically a calculation of how often manuscripts in a given journal are cited by future authors writing on a related subject. The number of citations parallels the importance of the article.

In 2016, the year assessed in the most recent report, JAAD was ranked number one in the field of dermatology with an Impact Factor of 7.002, up from 5.621 in 2015. This is the first time our Academy’s journal has attained this level of distinction, which complements our designation as the most widely read dermatology journal in the world.

This is an especially impressive accomplishment because clinical journals tend to have lower Impact Factors than research journals. Research-oriented journals are more frequently cited by investigators when they report the results of their research, whereas practitioners look to clinical journals to guide their daily patient care activities.

JAAD's top cited articles


1. Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification by Fine J.-D., Bruckner-Tuderman L., Eady R.A.J., Bauer E.A., Bauer J.W., Has C., Heagerty A., Hintner H., Hovnanian A., Jonkman M.F., Leigh I., Marinkovich M.P., Martinez A.E., McGrath J.A., Mellerio J.E., Moss C., Murrell D.F., Shimizu H., Uitto J., Woodley D., Zambruno G.

2. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies by Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K., Bergman J.N., Chamlin S.L., Cohen D.E., Cooper K.D., Cordoro K.M., Davis D.M., Feldman S.R., Hanifin J.M., Margolis D.J., Silverman R.A., Simpson E.L., Williams H.C., Elmets C.A., Block J., Harrod C.G., Begolka W.S., Sidbury R.

3. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial by Thaci D., Blauvelt A., Reich K., Tsai T.-F., Vanaclocha F., Kingo K., Ziv M., Pinter A., Hugot S., You R., Milutinovic M.

4. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis Work Group by Eichenfield L.F., Tom W.L., Chamlin S.L., Feldman S.R., Hanifin J.M., Simpson E.L., Berger T.G., Bergman J.N., Cohen D.E., Cooper K.D., Cordoro K.M., Davis D.M., Krol A., Margolis D.J., Paller A.S., Schwarzenberger K., Silverman R.A., Williams H.C., Elmets C.A., Block J., Harrod C.G., Smith Begolka W., Sidbury R.

5. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) by Papp K., Reich K., Leonardi C.L., Kircik L., Chimenti S., Langley R.G.B., Hu C., Stevens R.M., Day R.M., Gordon K.B., Korman N.J., Griffiths C.E.M.


The recent data confirms that we have been successful in threading the needle in presenting cutting edge, clinically relevant information of interest to the both the investigator and the practitioner. JAAD’s editorial team has grown the Impact Factor steadily over the past several years by seeking and publishing articles that correlate with readers’ interests and influence the practice of dermatology in significant ways.

The success of JAAD is the product of a team effort among our authors, the JAAD editorial board, our external peer reviewers, and the Academy staff. We are working on new initiatives to ensure we maintain our high level of impact and engagement.

In 2009, JAAD was voted one of the 100 most influential journals of the past 100 years by the Special Libraries Association.  We are proud to represent the Academy at the forefront of advances in academic and clinical dermatology.